SCHEMBL2129781

SCHEMBL2129781

FC(F)(F)c1ccc(Cl)cn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.58
NFE2L2 Q16236 2/20 0.39
HSD17B10 Q99714 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CASP3 P42574 1/20 0.38
P2RX7 Q99572 1/20 0.37
CYP19A1 P11511 3/20 0.37
P2RX3 P56373 1/20 0.37
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
ADRA2A P08913 2/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
LCK P06239 1/20 0.36
PGR P06401 1/20 0.36
CSF1R P07333 1/20 0.36
CHRM2 P08172 1/20 0.36
HTR1A P08908 1/20 0.36
PDGFRB P09619 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29937655 1.00 TRPV4 (0.58) TRPV4NFE2L2HSD17B10KDM4EALDH1A1
SCHEMBL24400761 0.88 TRPV4 (0.47) TRPV4ALDH1A1CYP19A1L3MBTL1
Pyridine SCHEMBL20135748 0.87 TRPV4 (0.46) TRPV4KDM4EALDH1A1P2RX7CYP19A1
SCHEMBL25886965 0.82 NFE2L2 (0.41) TRPV4NFE2L2CYP19A1ADRA2AKCNH2
SCHEMBL21994683 0.82 TRPV4 (0.39) TRPV4NFE2L2ALDH1A1CYP19A1ADRA2A
SCHEMBL25012763 0.82 TRPV4 (0.39) TRPV4NFE2L2CYP19A1ADRA2AL3MBTL1
SCHEMBL25894823 0.82 TRPV4 (0.39) TRPV4NFE2L2CYP19A1ADRA2AKCNH2
SCHEMBL24400564 0.81 LCK (0.44) TRPV4P2RX3ADRA2ACNR1CNR2
SCHEMBL26107386 0.81 ABL1 (0.48) TRPV4KDM4EADRA2AL3MBTL1ADRA2B
SCHEMBL24400563 0.79 P2RX7 (0.41) TRPV4P2RX7P2RX3CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118284105-A Composite material, preparation method thereof, light-emitting device and display device TCL科技集团股份有限公司 2024-07-02 CN claimed
EP-2831044-B1 METHODS FOR PREPARING 3-SUBSTITUTED-6-TRIFLUOROMETHYL PYRIDINES AND METHODS FOR USING 6-TRICHLOROMETHYL HALOGENATED PYRIDINES DOW AGROSCIENCES LLC (US) 2020-11-11 EP claimed
EP-2831044-A1 METHODS FOR PREPARING 3-SUBSTITUTED-6-TRIFLUOROMETHYL PYRIDINES AND METHODS FOR USING 6-TRICHLOROMETHYL HALOGENATED PYRIDINES Dow AgroSciences LLC (US) 2015-02-04 EP claimed
CN-104321310-A Process for preparing 3-substituted-6-trifluoromethylpyridines and process for using 6-trichloromethyl halopyridines DOW AGROSCIENCES LLC 2015-01-28 CN claimed
US-8785650-B2 Methods for preparing 3-substituted-6-trifluoromethyl pyridines and methods for using 6-trichloromethyl halogenated pyridines DOW AGROSCIENCES, LLC. (US) 2014-07-22 US claimed
US-20130261310-A1 METHODS FOR PREPARING 3-SUBSTITUTED-6-TRIFLUOROMETHYL PYRIDINES AND METHODS FOR USING 6-TRICHLOROMETHYL HALOGENATED PYRIDINES CORTEVA AGRISCIENCE LLC 2013-10-03 US claimed
WO-2013148338-A1 METHODS FOR PREPARING 3-SUBSTITUTED-6-TRIFLUOROMETHYL PYRIDINES AND METHODS FOR USING 6-TRICHLOROMETHYL HALOGENATED PYRIDINES DOW AGROSCIENCES LLC (US) 2013-10-03 WO claimed
US-12538924-B2 Pesticidally active heterocyclic derivatives with sulfur containing substituents SYNGENTA CROP PROTECTION AG (CH) 2026-02-03 US disclosed
US-20250092016-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES NOVARTIS AG (CH) 2025-03-20 US disclosed
CN-111057024-B Sydney ketone and Sydney ketimine compound, and preparation method and application thereof 华东理工大学 2025-02-07 CN disclosed
US-20250034170-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2025-01-30 US disclosed
EP-4415706-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF Vanqua Bio, Inc. (US) 2024-08-21 EP disclosed
CN-118284105-A Composite material, preparation method thereof, light-emitting device and display device TCL科技集团股份有限公司 2024-07-02 CN disclosed
WO-2009078983-A1 TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2009-06-25 WO disclosed
US-7504508-B2 PGD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-03-17 US disclosed
US-20090023782-A1 INCREASING PLANT VIGOR DOW AGROSCIENCES LLC (IN) 2009-01-22 US disclosed
EP-1740547-A1 PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-01-10 EP disclosed
US-20060286404-A1 Light emission material and organic electroluminescent device using the same AU OPTRONICS CORP. (TW) 2006-12-21 US disclosed
US-20050256158-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARMACEUTICALS, INC. 2005-11-17 US disclosed
WO-2005100321-A1 PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034170-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF GBA1, GAA, GBA2 TRPV4 4167/4885NFE2L2 2691/4885HSD17B10 1484/4885
US-20090023782-A1 INCREASING PLANT VIGOR HDLBP, VPS4B, VPS28 TRPV4 3503/4885NFE2L2 855/4885HSD17B10 1157/4885
US-12538924-B2 Pesticidally active heterocyclic derivatives with sulfur containing substituents CBR3, CBR1, CYCS TRPV4 2936/4885NFE2L2 1878/4885HSD17B10 1576/4885
US-20130261310-A1 METHODS FOR PREPARING 3-SUBSTITUTED-6-TRIFLUOROMETHYL PYRIDINES AND METHODS FOR USING 6-TRICHLOROMETHYL HALOGENATED PYRIDINES CYP4F3, CBR3, PRDX6 TRPV4 4466/4885NFE2L2 3688/4885HSD17B10 2934/4885
US-20250092016-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES ACE2, ACE, TMPRSS2 TRPV4 4257/4885NFE2L2 991/4885HSD17B10 576/4885
US-20050256158-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases PTGDR2, LTB4R2, CYSLTR2 TRPV4 860/4885NFE2L2 460/4885HSD17B10 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.